OncoMatch/Clinical Trials/NCT06797999
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Is NCT06797999 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Antibody-drug conjugate (ADC) for metastatic soft tissue sarcoma.
Treatment: Antibody-drug conjugate (ADC) — The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: cytotoxic chemotherapy — metastatic/unresectable
Prior treatment with at least one but no more than two lines of cytotoxic systemic therapy for metastatic/unresectable disease
Cannot have received: systemic anticancer therapy
Patients who have had systemic anticancer therapy, including any investigational agent within 4 weeks or 5 half-lives (whichever is shorter) prior to study treatment administration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Colorado Denver · Aurora, Colorado
- University of Miami - Sylvester Comprehensive Cancer Center · Miami, Florida
- Memorial Sloan Kettering Cancer Center · New York, New York
- University Of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify